Mitchell E. Levinson - 19 Aug 2021 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Reporting relationship: Chief Strategy Officer, Director
Issuer ticker: PLSE
Reported as of: 19 Aug 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Aug 2021, 16:22:05 UTC
Prior SEC filing: 21 May 2021
Next SEC filing: 24 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Sandra Gardiner, as Attorney-in-Fact

Key filing fact

Mitchell E. Levinson filed Form 4 for Pulse Biosciences, Inc. (PLSE) on 20 Aug 2021.

Key facts

This page summarizes Mitchell E. Levinson's Form 4 filing for Pulse Biosciences, Inc. (PLSE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Aug 2021, 16:22.

Change

Previous filing in this sequence was filed on 21 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLSE transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +65,510
Change %
Price: $0.000000
Shares after: 65,510
Date: 19 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,510
Exercise price: $21.12
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

50% of the shares subject to the option will vest in equal annual installments on the second, third and fourth anniversary of the grant date, and the other 50% of the shares subject to the option will vest upon the achievement of performance objectives established by the Compensation Committee of the Issuer, with vesting targets set at 25% (8,188 option shares) over the following four years on the anniversary of the grant date. All vesting is subject to the Reporting Person's continued service through each vesting date.